Title:
COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP
Document Type and Number:
WIPO Patent Application WO/2018/108084
Kind Code:
A1
Abstract:
Provided is a compound containing a tricyclic heteroaryl group. Specifically, provided are a compound (the definitions of groups are as stated in the description) having a structure as shown in formula (I), a pharmaceutical composition containing the compound of formula (I), and the compound, and isotopic derivatives, chiral isomers, allosterisms, different salts, prodrugs, formulations, etc. The present invention can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, and JAK), so that many related diseases, such as different tumors, nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF) can be treated.
More Like This:
| JP5802136 | Compositions and Methods for Inhibition of the JAK Pathway |
| WO/2010/006704 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS |
| WO/2006/023083 | MITOTIC KINESIN INHIBITORS |
Inventors:
ZHANG HANCHENG (CN)
LIU SHIFENG (CN)
YE XIANGYANG (CN)
LIU SHIFENG (CN)
YE XIANGYANG (CN)
Application Number:
PCT/CN2017/115756
Publication Date:
June 21, 2018
Filing Date:
December 12, 2017
Export Citation:
Assignee:
HANGZHOU INNOGATE PHARMA CO LTD (CN)
International Classes:
C07D498/04; A61K31/5383; A61P1/16; A61P11/00; A61P35/00; C07D519/00
Domestic Patent References:
| WO2017118438A1 | 2017-07-13 | |||
| WO1997019089A1 | 1997-05-29 | |||
| WO2016197987A1 | 2016-12-15 | |||
| WO2017101763A1 | 2017-06-22 |
Foreign References:
| CN105664178A | 2016-06-15 |
Other References:
CELL, vol. 100, 2000, pages 113 - 127
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 352, 2005, pages 786 - 792
See also references of EP 3553064A4
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 352, 2005, pages 786 - 792
See also references of EP 3553064A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: